Veralox Therapeutics
company
About
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes.
- 1 - 10
Highlights
Details
- Last Funding Type
- Seed
- Last Funding Money Raised
- $5.40M
- Industries
- Biotechnology,Medical,Pharmaceutical,Therapeutics
- Founded date
- Jan 1, 2017
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$22M
Veralox Therapeutics has raised a total of
$22M
in funding over 2 rounds. Their latest funding was raised on
Jun 16, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 16, 2021 | Series A | $16.60M | 1 | — | — | Detail |
| Sep 5, 2019 | Seed | $5.40M | 3 |
Sanofi
VTC Seed Fund
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
2
3
Veralox Therapeutics is funded by 3 investors.
Sanofi
and VTC Seed Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Sanofi
|
Yes | Seed |
|
VTC Seed Fund
|
Yes | Seed |
TEDCO
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
